loading...| Preferred Name |
Multi-mode Kinase Inhibitor EOC317 |
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164211 |
| CAS_Registry |
939805-30-8 |
| code |
C164211 |
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C177537 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923 |
| Contributing_Source |
GDC FDA |
| DEFINITION |
An orally available, small molecule, multi-mode kinase inhibitor (MMKI), with potential antineoplastic activity. Upon oral administration, MMKI EOC317 targets, binds to and inhibits the activity of a variety of kinases, such as phosphatidylinositol 3 kinase (PI3K), and the receptor tyrosine kinases, fibroblast growth factor receptor (FGFR), angiopoietin-1 receptor (TIE 2), and vascular endothelial growth factor receptor-2 (VEGFR-2). This inhibition may result in an induction of apoptosis of susceptible tumors cells in which these kinases are overexpressed. |
| FDA_UNII_Code |
44750KD9OE |
| FULL_SYN |
EOC-317 EDP317 EOC 317 EOC317 ONC201MMKI EOC317 Multi-mode Kinase Inhibitor EOC317 Urea, N-[4-[4-amino-6-(methoxymethyl)-7-(4-morpholinylmethyl)pyrrolo[2,1-f][1,2,4]triazin-5-yl]-2-fluorophenyl]-N'-[2-fluoro-5-(trifluoromethyl)phenyl]- ACTB-1003 |
| Is_Value_For_GDC_Property | |
| label |
Multi-mode Kinase Inhibitor EOC317 |
| Maps_To |
Multi-mode Kinase Inhibitor EOC317 |
| NCI_Drug_Dictionary_ID |
799401 |
| NCI_META_CUI |
CL977499 |
| PDQ_Closed_Trial_Search_ID |
799401 |
| PDQ_Open_Trial_Search_ID |
799401 |
| Preferred_Name |
Multi-mode Kinase Inhibitor EOC317 |
| prefixIRI |
Thesaurus:C164211 |
| prefLabel |
Multi-mode Kinase Inhibitor EOC317 |
| Semantic_Type |
Pharmacologic Substance |
| subClassOf |
| Delete | Mapping To | Ontology | Source |
|---|---|---|---|
| There are currently no mappings for this class. | |||